{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:13:14Z","timestamp":1787847194390,"version":"build-2784847793"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["2011-873"],"award-info":[{"award-number":["2011-873"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0230383","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T17:36:51Z","timestamp":1584639411000},"page":"e0230383","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Adjunctive rifampin for the treatment of Staphylococcus aureus\u00a0bacteremia with deep infections: A meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"given":"Huan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lengyue","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3029-9624","authenticated-orcid":true,"given":"Zhengxiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"pone.0230383.ref001","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","article-title":"Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997\u20131999.","volume":"2","author":"DJ Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"key":"pone.0230383.ref002","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress","volume":"293","author":"VG Fowler","year":"2005","journal-title":"JAMA"},{"key":"pone.0230383.ref003","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-001-1134-6","article-title":"Osteomyelitis: etiology, diagnosis, treatment and outcome in a public versus a private institution.","volume":"29","author":"F Lobati","year":"2001","journal-title":"Infection"},{"key":"pone.0230383.ref004","unstructured":"Health Protection Agency: Voluntary reporting of Staphylococcus aureus bacteremia in England, Wales, and Northern Ireland January\u2013December 2008. http:\/\/www.hpa.org.uk\/web\/HPAwebFile\/HPAweb_C\/1258560519595."},{"key":"pone.0230383.ref005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bmj.38834.421713.2F","article-title":"Mortality after Staphylococcus aureus bacteremia in two hospitals in Oxfordshire, 1997\u20132003: cohort study.","volume":"333","author":"DH Wyllie","year":"2006","journal-title":"BMJ"},{"key":"pone.0230383.ref006","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"RM Klevens","year":"2007","journal-title":"JAMA"},{"key":"pone.0230383.ref007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/499367","article-title":"Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992\u20132003.","volume":"42","author":"RM Klevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"pone.0230383.ref008","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"C Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0230383.ref009","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jac\/dkp065","article-title":"Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.","volume":"63","author":"K Gould F","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0230383.ref010","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1086\/519470","article-title":"Limitations of vancomycin in the management of resistant staphylococcal infections","volume":"45","author":"MH Kollef","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0230383.ref011","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/519471","article-title":"Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"45","author":"ST Micek","year":"2007","journal-title":"Clin Infect Dis"},{"key":"pone.0230383.ref012","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1086\/605572","article-title":"Vancomycin in Combination with Other Antibiotics for the Treatment of Serious Methicillin\u2010Resistant\\r, Staphylococcus aureus\\r, Infections","volume":"49","author":"Deresinski Stan","year":"2009","journal-title":"Clin Infect Dis"},{"key":"pone.0230383.ref013","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s00586-008-0778-7","article-title":"Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis","volume":"17","author":"Z Ge","year":"2008","journal-title":"Eur Spine J"},{"key":"pone.0230383.ref014","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1128\/AAC.38.5.1059","article-title":"Antibiotic penetration of and bactericidal activity within endothelial cells","volume":"38","author":"RO Darouiche","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0230383.ref015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archinte.168.8.805","article-title":"Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature","volume":"168","author":"J Perlroth","year":"2008","journal-title":"Arch Intern Med"},{"key":"pone.0230383.ref016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/CMR.00034-09","article-title":"Rifampin combination therapy for nonmycobacterial infections","volume":"23","author":"GN Forrest","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"pone.0230383.ref017","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1086\/506568","article-title":"Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants","volume":"43","author":"J. C. Hageman","year":"2006","journal-title":"Clin. Infect. Dis"},{"key":"pone.0230383.ref018","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1099\/jmm.0.072280-0","article-title":"Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteremia: a systematic review","volume":"63","author":"CD Russell","year":"2014","journal-title":"J Med Microbiol"},{"key":"pone.0230383.ref019","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1345\/aph.1R726","article-title":"Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?","volume":"47","author":"S Tremblay","year":"2013","journal-title":"Ann Pharmacother"},{"key":"pone.0230383.ref020","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"key":"pone.0230383.ref021","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses.","author":"GA Wells","year":"2005"},{"key":"pone.0230383.ref022","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1093\/clinids\/5.Supplement_3.S515","article-title":"Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections","volume":"53","author":"P Van der Auwera","year":"1983","journal-title":"Rev Infect Dis"},{"key":"pone.0230383.ref023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.28.4.467","article-title":"Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections","volume":"28","author":"P Van der Auwera","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0230383.ref024","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicilin-resistant Staphylococcus aureus endocarditis.","volume":"115","author":"DP Levine","year":"1991","journal-title":"An. Int. Med"},{"key":"pone.0230383.ref025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2796.2005.01598.x","article-title":"Levofloxacin does not decrease mortality in Staphylococcus aureus bacteremia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients","volume":"259","author":"E Ruotsalainen","year":"2006","journal-title":"J Intern Med"},{"key":"pone.0230383.ref026","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1128\/AAC.00300-08","article-title":"Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus","volume":"52","author":"DJ Riedel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0230383.ref027","doi-asserted-by":"crossref","first-page":"e0122824","DOI":"10.1371\/journal.pone.0122824","article-title":"Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus\u2014a retrospective cohort study.","volume":"10","author":"E Forsblom","year":"2015","journal-title":"PLOS ONE"},{"key":"pone.0230383.ref028","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteremia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"391","author":"GE Thwaites","year":"2018","journal-title":"Lancet"},{"key":"pone.0230383.ref029","first-page":"112","article-title":"Antimicrobial penetration into polymorphonuclear leukocytes and alveolar macrophages.","volume":"6","author":"MB Murdoch","year":"1991","journal-title":"Semin Respir Infect"},{"key":"pone.0230383.ref030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/infdis\/125.5.486","article-title":"Killing of Intraleukocytie Staphylococcus aureus by Rifampin: In-Vitro and In-Vivo Studies","volume":"125","author":"L Mandell G","year":"1972","journal-title":"J Infect Dis"},{"key":"pone.0230383.ref031","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial rna polymerase","volume":"104","author":"EA Campbell","year":"2001","journal-title":"Cell"},{"key":"pone.0230383.ref032","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CCM.0b013e3181b9ecea","article-title":"Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia.","volume":"38","author":"YJ Jung","year":"2010","journal-title":"Crit Care Med"},{"key":"pone.0230383.ref033","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/CCM.0b013e3181db7d28","article-title":"Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment","volume":"38","author":"CK Tan","year":"2010","journal-title":"Crit Care Med"},{"key":"pone.0230383.ref034","first-page":"73","article-title":"Treatment of methicillin resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin","volume":"82","author":"NK Henry","year":"1987","journal-title":"Am J Med"},{"key":"pone.0230383.ref035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1532-5415.2010.02842.x","article-title":"Emergence of rifampicin resistance during rifampicin-containing treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.","volume":"58","author":"CC Lai","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"pone.0230383.ref036","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10096-005-0063-1","article-title":"Emergence and spread of rifampicin resistant, methicillin-resistant Staphylococcus aureus during vancomycin rifampicin combination therapy in an intensive care unit","volume":"25","author":"O Ju","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"pone.0230383.ref037","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/03007990903512057","article-title":"The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.","volume":"26","author":"GE Stein","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"pone.0230383.ref038","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/38.5.865","article-title":"Penetration of vancomycin into human lung tissue","volume":"38","author":"M Cruciani","year":"1996","journal-title":"J. Antimicrob. Chemother"},{"key":"pone.0230383.ref039","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/27.suppl_B.9","article-title":"Penetration into tissues of various drugs active against gram-positive bacteria","volume":"27","author":"A Kropec","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"pone.0230383.ref040","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.42.10.2626","article-title":"Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space","volume":"42","author":"T Mindermann","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0230383.ref041","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/infdis\/151.1.157","article-title":"Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations","volume":"151","author":"S Bayer A","year":"1985","journal-title":"J Infect Dis"},{"key":"pone.0230383.ref042","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1128\/AAC.48.10.4016-4019.2004","article-title":"In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations","volume":"48","author":"SA Shelburne","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0230383.ref043","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1128\/AAC.46.4.1122-1124.2002","article-title":"Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.","volume":"46","author":"Saleh-Mghir Azzam","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0230383.ref044","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1128\/AAC.23.6.932","article-title":"Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci","volume":"23","author":"FD Lowy","year":"1983","journal-title":"Antimicrob. Agents Chemother"},{"key":"pone.0230383.ref045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/144.4.365","article-title":"Antistaphylococcal activity of rifampin with other antibiotics","volume":"144","author":"H Zinner S","year":"1981","journal-title":"J Infect Dis"},{"issue":"suppl 3","key":"pone.0230383.ref046","doi-asserted-by":"crossref","first-page":"S491","DOI":"10.1093\/clinids\/5.Supplement_3.S491","article-title":"Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents","volume":"5","author":"CW Norden","year":"1983","journal-title":"Rev Infect Dis"},{"key":"pone.0230383.ref047","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.26.2.220","article-title":"Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus","volume":"26","author":"AS Bayer","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0230383.ref048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions.","volume":"29","author":"AM Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"pone.0230383.ref049","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1592\/phco.27.3.476","article-title":"Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin.","volume":"27","author":"BC Gebhart","year":"2007","journal-title":"Pharmacotherapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T17:37:24Z","timestamp":1584639444000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230383"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0230383","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]}}}